These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12839273)

  • 1. Endothelins in chronic diabetic complications.
    Khan ZA; Chakrabarti S
    Can J Physiol Pharmacol; 2003 Jun; 81(6):622-34. PubMed ID: 12839273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of endothelin receptor antagonists in diabetes.
    Chakrabarti S; Cukiernik M; Mukherjee S; Chen S
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2873-88. PubMed ID: 11093358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of endothelins: a common pathogenetic mechanism in chronic diabetic complications.
    Chakrabarti S; Khan ZA; Cukiernik M; Fukuda G; Chen S; Mukherjee S
    Int J Exp Diabetes Res; 2002; 3(4):217-31. PubMed ID: 12546275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelin in hypertension.
    Schiffrin EL
    Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor antagonists in preclinical models of pulmonary hypertension.
    Pullamsetti SS; Schermuly RT
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():3-13. PubMed ID: 19335741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelins: regulators of extracellular matrix protein production in diabetes.
    Khan ZA; Farhangkhoee H; Mahon JL; Bere L; Gonder JR; Chan BM; Uniyal S; Chakrabarti S
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1022-9. PubMed ID: 16741042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endothelins in animal models of hypertension: focus on cardiovascular protection.
    Moreau P; Schiffrin EL
    Can J Physiol Pharmacol; 2003 Jun; 81(6):511-21. PubMed ID: 12839263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The endothelin system and its antagonism in chronic kidney disease.
    Dhaun N; Goddard J; Webb DJ
    J Am Soc Nephrol; 2006 Apr; 17(4):943-55. PubMed ID: 16540557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
    Kim W; Hudson BI; Moser B; Guo J; Rong LL; Lu Y; Qu W; Lalla E; Lerner S; Chen Y; Yan SS; D'Agati V; Naka Y; Ramasamy R; Herold K; Yan SF; Schmidt AM
    Ann N Y Acad Sci; 2005 Jun; 1043():553-61. PubMed ID: 16037278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linking the beneficial effects of current therapeutic approaches in diabetes to the vascular endothelin system.
    Matsumoto T; Lopes RA; Taguchi K; Kobayashi T; Tostes RC
    Life Sci; 2014 Nov; 118(2):129-35. PubMed ID: 24418002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between lipoprotein(a) and the complications of diabetes mellitus.
    Koschinsky ML; Marcovina SM
    Acta Diabetol; 2003 Jun; 40(2):65-76. PubMed ID: 12861403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction.
    Sorrentino FS; Matteini S; Bonifazzi C; Sebastiani A; Parmeggiani F
    Eye (Lond); 2018 Jul; 32(7):1157-1163. PubMed ID: 29520046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of serum endothelin in type 2 diabetic patients with vascular complications].
    Fang YH; Zhang JP; Zhou SX; Zheng JF; Yu YW; Yan SG; Fan WK; Chen YS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):1007-8, 1011. PubMed ID: 16109562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus.
    Nett PC; Ortmann J; Celeiro J; Haas E; Hofmann-Lehmann R; Tornillo L; Terraciano LM; Barton M
    Life Sci; 2006 Apr; 78(19):2213-8. PubMed ID: 16300798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin as a clinical target in the treatment of systemic hypertension.
    Prasad VS; Palaniswamy C; Frishman WH
    Cardiol Rev; 2009; 17(4):181-91. PubMed ID: 19525680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endothelins. I. Physiology].
    Jensovský J
    Cas Lek Cesk; 1994 Jan; 133(2):46-9. PubMed ID: 8131179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study on prevalence rates of hypertension and chronic diabetic complications of in-patients with diabetes].
    Xiang HD
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Sep; 24(9):819-21. PubMed ID: 14521777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts.
    Jesmin S; Zaedi S; Shimojo N; Iemitsu M; Masuzawa K; Yamaguchi N; Mowa CN; Maeda S; Hattori Y; Miyauchi T
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1030-40. PubMed ID: 17148754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.